Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity

Neuropharmacology

Volumn 75, Issue , 2013, Pages 356-364

  Qin, Rongyin ^a,b   Chen, Yingzhu ^a   Li, Ming ^b  

^a CLINICAL MEDICAL COLLEGE OF YANGZHOU UNIVERSITY   (China)

^b UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Asenapine; Clozapine; Conditioned avoidance response; Locomotor activity; Olanzapine; Phencyclidine; Sensitization; Tolerance

Indexed keywords

ASENAPINE; CLOZAPINE; OLANZAPINE; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPSYCHOTIC ACTIVITY; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG SENSITIZATION; HYPERLOCOMOTION; MALE; MOTOR DYSFUNCTION; NONHUMAN; PHASE TRANSITION; PRIORITY JOURNAL; RAT; TREATMENT INDICATION;

ASENAPINE; CLOZAPINE; CONDITIONED AVOIDANCE RESPONSE; LOCOMOTOR ACTIVITY; OLANZAPINE; PHENCYCLIDINE; SENSITIZATION; TOLERANCE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BENZODIAZEPINES; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HYPERKINESIS; MALE; MOTOR ACTIVITY; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84883756736     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.05.031     Document Type: Article

References (46)

1. T. Abekawa, K. Ito, and T. Koyama Different effects of a single and repeated administration of clozapine on phencyclidine-induced hyperlocomotion and glutamate releases in the rat medial prefrontal cortex at short- and long-term withdrawal from this antipsychotic Naunyn Schmiedebergs Arch. Pharmacol. 375 2007 261 271 (Pubitemid 46701627)
2. J. Arnt Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine Eur. J. Pharmacol. 283 1995 55 62
3. J.B. Atkins, J. Chlan-Fourney, H.E. Nye, N. Hiroi, W.A. Carlezon Jr., and E.J. Nestler Region-specific induction of deltaFosB by repeated administration of typical versus atypical antipsychotic drugs Synapse 33 1999 118 128 (Pubitemid 29319289)
4. Y.K. Choi, E.H. Wong, B. Henry, M. Shahid, and F.I. Tarazi Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors Int. J. Neuropsychopharmacol. 13 2010 405 410
5. M.M. Doat-Meyerhoefer, R. Hard, J.C. Winter, and R.A. Rabin Effects of clozapine and 2,5-dimethoxy-4-methylamphetamine [DOM] on 5-HT2A receptor expression in discrete brain areas Pharmacol. Biochem. Behav. 81 2005 750 757 (Pubitemid 41187807)
6. J.D. Elsworth, S.M. Groman, J.D. Jentsch, R. Valles, M. Shahid, E. Wong, H. Marston, and R.H. Roth Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration Neuropharmacology 62 2012 1442 1452
7. M. Feng, N. Sui, and M. Li Avoidance disruptive effect of clozapine and olanzapine is potentiated by increasing the test trials: further test of the motivational salience hypothesis Pharmacol. Biochem. Behav. 103 2012 467 473
8. M. Feng, N. Sui, and M. Li Environmental and behavioral controls of the expression of clozapine tolerance: evidence from a novel across-model transfer paradigm Behav. Brain Res. 238 2013 178 187
9. O. Franberg, M.M. Marcus, and T.H. Svensson Involvement of 5-HT(2A) receptor and alpha(2)-adrenoceptor blockade in the asenapine-induced elevation of prefrontal cortical monoamine outflow Synapse 66 2012 650 660
10. O. Franberg, C. Wiker, M.M. Marcus, A. Konradsson, K. Jardemark, B. Schilstrom, M. Shahid, E.H. Wong, and T.H. Svensson Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia Psychopharmacology (Berl.) 196 2008 417 429 (Pubitemid 351200428)
11. S.D. Gleason, and H.E. Shannon Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice Psychopharmacology (Berl) 129 1997 79 84 (Pubitemid 27037454)
12. R.H. Howland Update on newer antipsychotic drugs J. Psychosoc Nurs. Ment. Health Serv. 49 2011 13 15
13. M. Huang, Z. Li, J. Dai, M. Shahid, E.H. Wong, and H.Y. Meltzer Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus Neuropsychopharmacology 33 2008 2934 2945
14. M. Kalinichev, M.J. Robbins, E.M. Hartfield, P.R. Maycox, S.H. Moore, K.M. Savage, N.E. Austin, and D.N. Jones Comparison between intraperitoneal and subcutaneous phencyclidine administration in Sprague-Dawley rats: a locomotor activity and gene induction study Prog. Neuropsychopharmacol. Biol. Psychiatry 32 2008 414 422 (Pubitemid 351178957)
15. S. Kapur, S.C. VanderSpek, B.A. Brownlee, and J.N. Nobrega Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy J. Pharmacol. Exp. Ther. 305 2003 625 631 (Pubitemid 36459179)
16. M. Li, P.J. Fletcher, and S. Kapur Time course of the antipsychotic effect and the underlying behavioral mechanisms Neuropsychopharmacology 32 2007 263 272 (Pubitemid 46106933)
17. M. Li, W. He, and A. Mead An investigation of the behavioral mechanisms of antipsychotic action using a drug-drug conditioning paradigm Behav. Pharmacol. 20 2009 184 194
18. M. Li, W. He, and A. Mead Olanzapine and risperidone disrupt conditioned avoidance responding in phencyclidine-pretreated or amphetamine-pretreated rats by selectively weakening motivational salience of conditioned stimulus Behav. Pharmacol. 20 2009 84 98
19. M. Li, T. Sun, and A. Mead Clozapine, but not olanzapine, disrupts conditioned avoidance response in rats by antagonizing 5-HT(2A/2C) receptors J. Neural Transm. 119 2012 497 505
20. M. Li, T. Sun, C. Zhang, and G. Hu Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning Psychopharmacology (Berl.) 212 2010 45 57
21. H.M. Marston, J.W. Young, F.D. Martin, K.A. Serpa, C.L. Moore, E.H. Wong, L. Gold, L.T. Meltzer, M.R. Azar, M.A. Geyer, and M. Shahid Asenapine effects in animal models of psychosis and cognitive function Psychopharmacology (Berl) 206 2009 699 714
22. S. Maurel-Remy, K. Bervoets, and M.J. Millan Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors Eur. J. Pharmacol. 280 1995 R9 R11
23. S.L. McLean, J.C. Neill, N.F. Idris, H.M. Marston, E.H. Wong, and M. Shahid Effects of asenapine, olanzapine, and risperidone on psychotomimetic- induced reversal-learning deficits in the rat Behav. Brain Res. 214 2010 240 247
24. A. Mead, and M. Li Avoidance-suppressing effect of antipsychotic drugs is progressively potentiated after repeated administration: an interoceptive drug state mechanism J. Psychopharmacol. 24 2010 1045 1053
25. H.Y. Meltzer Clozapine: balancing safety with superior antipsychotic efficacy Clin. Schizophr. Relat. Psychoses 6 2012 134 144
26. H.Y. Meltzer, A. Dritselis, U. Yasothan, and P. Kirkpatrick Asenapine Nat. Rev. Drug Discov. 8 2009 843 844
27. M.J. Millan, M. Brocco, A. Gobert, F. Joly, K. Bervoets, J. Rivet, A. Newman-Tancredi, V. Audinot, and S. Maurel Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat Eur. J. Neurosci. 11 1999 4419 4432 (Pubitemid 30009274)
28. T. Moran-Gates, L. Gan, Y.S. Park, K. Zhang, R.J. Baldessarini, and F.I. Tarazi Repeated antipsychotic drug exposure in developing rats: dopamine receptor effects Synapse 59 2006 92 100 (Pubitemid 43054378)
29. J. Qiao, H. Li, and M. Li Olanzapine sensitization and clozapine tolerance: from adolescence to adulthood in the conditioned avoidance response model Neuropsychopharmacology 38 2013 513 524
30. A.M. Redmond, A. Harkin, J.P. Kelly, and B.E. Leonard Effects of acute and chronic antidepressant administration on phencyclidine (PCP) induced locomotor hyperactivity Eur. Neuropsychopharmacol. 9 1999 165 170 (Pubitemid 29073698)
31. M. Shahid, G.B. Walker, S.H. Zorn, and E.H. Wong Asenapine: a novel psychopharmacologic agent with a unique human receptor signature J. Psychopharmacol. 23 2009 65 73
32. S. Snigdha, N. Idris, B. Grayson, M. Shahid, and J.C. Neill Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism Psychopharmacology (Berl) 214 2011 843 853
33. N.L. Sparkman, and M. Li Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia Behav. Pharmacol. 23 2012 658 668
34. T. Sun, G. Hu, and M. Li Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs Eur. J. Pharmacol. 602 2009 334 342
35. T. Sun, C. Zhao, G. Hu, and M. Li Iptakalim: a potential antipsychotic drug with novel mechanisms? Eur. J. Pharmacol. 634 2010 68 76
36. N. Swalve, and M. Li Parametric studies of antipsychotic-induced sensitization in the conditioned avoidance response model: roles of number of drug exposure, drug dose, and test-retest interval Behav. Pharmacol. 23 2012 380 391
37. D.S. Tait, H.M. Marston, M. Shahid, and V.J. Brown Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions Psychopharmacology (Berl) 202 2009 295 306
38. F.I. Tarazi, T. Moran-Gates, E.H. Wong, B. Henry, and M. Shahid Differential regional and dose-related effects of asenapine on dopamine receptor subtypes Psychopharmacology (Berl) 198 2008 103 111
39. F.I. Tarazi, T. Moran-Gates, E.H. Wong, B. Henry, and M. Shahid Asenapine induces differential regional effects on serotonin receptor subtypes J. Psychopharmacol. 24 2010 341 348
40. F.I. Tarazi, and J.C. Neill The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania Expert Opin. Drug Discov. 2012
41. F.I. Tarazi, and M. Shahid Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania Drugs Today (Barc) 45 2009 865 876
42. F.I. Tarazi, K. Zhang, and R.J. Baldessarini Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment J. Pharmacol. Exp. Ther. 297 2001 711 717 (Pubitemid 32378004)
43. C. Zhang, Y. Fang, and M. Li Olanzapine and risperidone disrupt conditioned avoidance responding by selectively weakening motivational salience of conditioned stimulus: further evidence Pharmacol. Biochem. Behav. 98 2011 155 160
44. C. Zhang, and M. Li Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine Behav. Pharmacol. 23 2012 66 79
45. C. Zhao, and M. Li Neuroanatomical substrates of the disruptive effect of olanzapine on rat maternal behavior as revealed by c-Fos immunoreactivity Pharmacol. Biochem. Behav. 103 2012 174 180
46. C. Zhao, T. Sun, and M. Li Neural basis of the potentiated inhibition of repeated haloperidol and clozapine treatment on the phencyclidine-induced hyperlocomotion Prog. Neuropsychopharmacol. Biol. Psychiatry 38 2012 175 182